Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

NCT00509496 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

NIH

Sponsor class

Stopped Low accrual

Conditions

Skin Cancer
Melanoma

Interventions

DRUG: fludarabine phosphate
DRUG: cyclophosphamide
BIOLOGICAL: aldesleukin
BIOLOGICAL: autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes
BIOLOGICAL: autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes

Sponsor

National Cancer Institute (NCI)